仁度生物涨2.10%，成交额666.51万元

Group 1 - The core viewpoint of the news is that Rendu Biotech has shown fluctuations in its stock performance, with a year-to-date increase of 34.89% and a recent drop of 10.11% over the past 20 days [1] - As of June 30, the number of shareholders for Rendu Biotech increased by 7.54% to 3,495, while the average circulating shares per person decreased by 7.01% to 9,032 shares [2] - The company reported a revenue of 81.24 million yuan for the first half of 2025, representing a year-on-year decrease of 6.27%, and a net profit of 2.04 million yuan, down 52.94% year-on-year [2] Group 2 - Rendu Biotech has a market capitalization of 1.93 billion yuan and its stock price was 48.09 yuan per share as of September 25 [1] - The company's main business revenue composition includes 90.04% from reagent business, 8.49% from instrument business, and 1.47% from testing services [1] - Since its A-share listing, Rendu Biotech has distributed a total of 20.58 million yuan in dividends [3]